NFE2L2 and cancer: Therefore, the NRF2/KEAP1 pathway has the role of a double-edged sword, and NRF2 inducers act to protect normal cells from carcinogens, whereas NRF2 inhibitors act to suppress the proliferation of cancer cells that evolved from persistent NRF2 activation due to mutations.